Abstracts Archive - Page 1311 of 2607 - ACR Meeting Abstracts

Abstract Number: 1870 • 2018 ACR/ARHP Annual Meeting
Phase 2 Trial of Induction Therapy with Anti-CD20 (Rituximab) Followed By Maintenance Therapy with Anti-BAFF (Belimumab) in Patients with Active Lupus Nephritis
Maria Dall'Era¹, Cynthia Aranow², Margaret Byron³, Linna Ding⁴, Dawn Smilek⁵, Betty Diamond⁶ and David Wofsy⁷, ¹University of California, San Francisco, San Francisco, CA, ²The Feinstein Institute for Medical Research, Manhasset, NY, ³Rho Federal Systems, Inc., Chapel Hill, NC, ⁴National Institute of Allergy and Infectious Diseases, Bethesda, MD, ⁵Immune Tolerance Network, San Francisco, CA, ⁶Autoimmune Musculoskeletal and Hematopoietic Diseases, The Feinstein Institute for Medical Research, Manhasset, NY, ⁷Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Two randomized, controlled trials of rituximab in patients with lupus and lupus nephritis (LN) did not meet their primary endpoints. A potential explanation is…
Abstract Number: 1871 • 2018 ACR/ARHP Annual Meeting
A High Cardiovascular Biomarker Panel Risk Score Is Associated with Increased 10-Year Risk of Cardiovascular Events and Death in SLE
Maureen A. McMahon¹, Jennifer M. Grossman², Lori Sahakian³, Christina Charles-Schoeman⁴, John Fitzgerald¹, Mihaela Taylor⁴, Alan Gorn¹, Eloise Olmos¹, Daniel J. Wallace⁵, Bevra H Hahn^1,4 and Brian Skaggs⁴, ¹Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Div of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ³UCLA David Geffen School of Medicine, Los Angeles, CA, ⁴Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁵Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA
Background/Purpose: There is a well-documented increase in atherosclerosis (ATH) in SLE that is not fully explained by traditional risk factors. Several non-Framingham biomarkers, including pro-inflammatory…
Abstract Number: 1872 • 2018 ACR/ARHP Annual Meeting
Safety and Efficacy of Allogeneic Umbilical Cord-Derived Mesenchymal Stem Cells in Patients with Systemic Lupus Erythematosus: Results of an Open-Label Phase I Study
Diane L. Kamen¹, Paul J. Nietert², Hongjun Wang³, Tara Duke³, Colleen Cloud³, Angela Robinson³ and Gary S. Gilkeson⁴, ¹Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ²Public Health Sciences, Medical University of South Carolina, Charleston, SC, ³Medical University of South Carolina, Charleston, SC, ⁴Department of Medicine, Medical University of South Carolina, Charleston, SC
Background/Purpose: Mesenchymal stem cells (MSCs) are known to possess significant immunosuppressive and tissue protective properties, and their use in refractory systemic lupus erythematosus (SLE) is…
Abstract Number: 1873 • 2018 ACR/ARHP Annual Meeting
Age- and Cause-Specific Standardized Mortality Ratio of Systemic Lupus Erythematosus Patients in Ontario, Canada over 43 Years (1971-2013)
Konstantinos Tselios, Dafna D Gladman, Barry Sheane, Jiandong Su and Murray Urowitz, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: The major causes of early death in systemic lupus erythematosus (SLE) include active disease and infections, while cardiovascular complications and malignancies dominate the late…
Abstract Number: 1874 • 2018 ACR/ARHP Annual Meeting
Remission and Low Disease Activity State Are Protective of Intermediate and Long-Term Outcomes in SLE Patients. Data from a Multi-Ethnic, Multi-Center US Cohort
Guillermo J. Pons-Estel^1,2, Graciela S. Alarcón³, Manuel Ugarte-Gil^4,5, Luis M. Vilá⁶, John D. Reveille⁷ and Gerald McGwin³, ¹Rheumatology, Hospital Provincial de Rosario, Rosario, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario. Argentina, Rosario, Argentina, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology, Universidad Científica del Sur, Lima, Peru, ⁵Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁶Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, ⁷McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: Over the last few years the importance of treating patients with SLE towards achieving either Remission or LDAS (Treat-to-Target approach) has become evident. We…
Abstract Number: 1875 • 2018 ACR/ARHP Annual Meeting
Influence of Setting an Upper Limit of the Modified Rodnan Skin Score As an Inclusion Criterion in Systemic Sclerosis Clinical Trials on the Ratio of Skin Fibrosis Progression Vs. Improvement – an Analysis of the Genisos Cohort
Carina Mihai^1,2, Rucsandra Dobrota^1,2, Shervin Assassi³, Maureen D. Mayes³ and Oliver Distler¹, ¹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Internal Medicine and Rheumatology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ³Rheumatology, University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: Recent studies on large cohorts of patients with systemic sclerosis (SSc) have shown that lowering the upper threshold of the modified Rodnan skin score…
Abstract Number: 1876 • 2018 ACR/ARHP Annual Meeting
Machine Learning Classification of Peripheral Blood Gene Expression Identifies a Subset of Patients with Systemic Sclerosis Most Likely to Show Clinical Improvement in Response to Hematopoietic Stem Cell Transplant
Jennifer Franks¹, Viktor Martyanov², Tammara A. Wood², Leslie Crofford³, Lynette Keyes-Elstein⁴, Daniel E. Furst⁵, Ellen Goldmuntz⁶, Maureen D. Mayes⁷, Peter McSweeney⁸, Richard Nash⁸, Keith Sullivan⁹ and Michael L. Whitfield¹⁰, ¹Geisel School of Medicine at Dartmouth, Hanover, NH, ²Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ³Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ⁴Rho, Inc, Chapel Hill, NC, ⁵University of California Los Angeles, Los Angeles, CA, ⁶NIAID, NIH, Bethesda, MD, ⁷Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁸Colorado Blood Cancer Institute, Denver, CO, ⁹Duke University Medical Center, Durham, NC, ¹⁰Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: The SCOT (Scleroderma: Cyclophosphamide or Transplantation) trial (Sullivan K. et al, 2018) demonstrated the clinical benefit of hematopoietic stem cell transplant (HSCT) compared to…
Abstract Number: 1877 • 2018 ACR/ARHP Annual Meeting
Specific Pneumoproteins Predict Progression of Interstitial Lung Disease in Systemic Sclerosis Patients Undergoing Treatment with Immunosuppression
Elizabeth R. Volkmann¹, Donald P. Tashkin¹, Masataka Kuwana², Ning Li³, Julio Charles⁴, Faye N. Hant⁵, Galina S. Bogatkevich⁶, Tanjina Akter⁶, Michael Roth⁷, Hyun J. Grace Kim⁸, Jonathan Goldin⁹, Dinesh Khanna¹⁰, Philip J. Clements¹¹, Daniel E. Furst⁷, Robert Elashoff¹², Rick Silver¹³ and Shervin Assassi¹⁴, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ³Biomathematics, University of California, Los Angeles, Los Angeles, CA, ⁴University of Texas Health Science Center at Houston, Houston, TX, ⁵Rheumatology, Medical University of South Carolina, Charleston, SC, ⁶Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ⁷Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁸Department of Radiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁹Department of Radiological Sciences at UCLA, University of California, Los Angeles, David Geffen School of Medicine, Santa Monica, CA, ¹⁰Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ¹¹Medicine, University of California, Los Angeles, Los Angeles, CA, ¹²University of California, Los Angeles, Los Angeles, CA, ¹³Rheumatology, Medical University of SC, Charleston, SC, ¹⁴University of Texas McGovern Medical School, Houston, TX
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in systemic sclerosis (SSc). While some SSc-ILD patients are stable or improve with immunosuppressive…
Abstract Number: 1878 • 2018 ACR/ARHP Annual Meeting
Immunosuppression in Diffuse Systemic Sclerosis Improves Outcomes Using a Novel Composite Response Index
Boyang Zheng¹, Mianbo Wang² and Murray Baron³, ¹Rheumatology, McGill University Health Center (MUHC), Montreal, QC, Canada, ²Lady Davis Institute for Medical Research, Montreal, QC, Canada, ³Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: Diffuse systemic sclerosis (dcSSc) is a devastating multi-organ disease where the mainstay of treatment is immunosuppression. Data on these therapies are mostly based on…
Abstract Number: 1879 • 2018 ACR/ARHP Annual Meeting
The Effects of Riociguat on Raynaud’s Phenomenon and Digital Ulcers in Patients with Diffuse Systemic Sclerosis: Results from the Phase IIb RISE-SSc Study
Dinesh Khanna¹, Yannick Allanore², Christopher P. Denton³, Masataka Kuwana⁴, Marco Matucci-Cerinic⁵, Janet E. Pope⁶, Janethe Pena⁷, Kaisa Laapas⁸, Zhen Yao⁹ and Oliver Distler¹⁰, ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²Rheumatology A Department, Cochin Hospital, Paris Descartes University, Sorbonne Paris Cité, Paris, France, ³UCL Division of Medicine, Royal Free Campus, London, United Kingdom, ⁴Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁵Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ⁶Department of Medicine, University of Western Ontario, London, ON, Canada, ⁷Clinical Development, Bayer US LLC, Whippany, NJ, ⁸StatFinn Oy, Espoo, Finland, ⁹Bayer AG, Berlin, Germany, ¹⁰Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of pulmonary arterial hypertension associated with connective tissue disease. It was anticipated that…
Abstract Number: 1880 • 2018 ACR/ARHP Annual Meeting
Cardiovascular (CV) Risk Factors and Atherosclerotic CV Events Among Incident Cases of Systemic Sclerosis: Results from a Population Based Cohort (1980-2016)
Avneek Singh Sandhu¹, Reto Kurmann², Cynthia S. Crowson³, Rekha Mankad², Eric L. Matteson⁴, Thomas Osborn¹, Kenneth J. Warrington⁵ and Ashima Makol¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Cardiovascular Diseases, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁴Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁵Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: Cardiac involvement, due to impairment of coronary microcirculation and myocardial fibrosis, affects prognosis in individuals with SSc, and represents one of the leading causes…
Abstract Number: 1881 • 2018 ACR/ARHP Annual Meeting
Discovery and Validation of Novel Disease Subsets in 806 Patients with Takayasu’s Arteritis across Four International Cohorts
Ruchika Goel¹, Katherine B. Gribbons², Kathleen Maksimowicz-McKinnon³, Gary S. Hoffman⁴, Sathish Kumar⁵, George Joseph⁶, Raheesh Ravindran⁷, Aswin Nair⁸, David Cuthbertson⁹, Simon Carette¹⁰, Nader A. Khalidi¹¹, Curry L. Koening¹², Carol Langford¹³, Carol A. McAlear¹⁴, Paul A. Monach¹⁵, Larry W. Moreland¹⁶, Christian Pagnoux¹⁷, Philip Seo¹⁸, Antoine G. Sreih¹⁹, Kenneth J. Warrington²⁰, Steven R. Ytterberg²⁰, Peter A. Merkel²¹, Debashish Danda²² and Peter C. Grayson², ¹Rheumatology, Christian Medical College, Vellore Tamilnadu, India, ²National Institute of Arthritis, Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD, ³Rheumatology, Henry Ford Hospital, Detroit, MI, ⁴Rheumatology, Cleveland Clinic, Cleveland, OH, ⁵Child Health, Christian Medical College, Vellore, India, ⁶Cardiology, Christian Medical College, Vellore, India, ⁷Department of Clinical Immunology and Rheumatology, Christian Medical College, Vellore, India, ⁸Clinical Immunology and Rheumatology, Christian Medical College, Vellore, India, ⁹Biostatistics and Informatics, Department of Pediatrics, Department of Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ¹⁰Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ¹¹Rheumatology, McMaster University, Hamilton, ON, Canada, ¹²Rheumatology, Division of Rheumatology, University of Utah, Salt Lake City, UT, ¹³Rheumatic and Immunologic Diseases, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹⁴Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁵Section of Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁶Division of Rheumatology and Clinical Immunology, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹⁷Division of Rheumatology, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ¹⁸Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ¹⁹Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²⁰Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN, ²¹University of Pennsylvania, Philadelphia, PA, ²²Clinical Immunology & Rheumatology, Christian Medical College, Vellore, India, Vellore, India
Background/Purpose: Takayasu’s arteritis (TAK) is characterized by variable patterns of damage throughout the large arteries. This study aimed to develop and validate a novel disease…
Abstract Number: 1882 • 2018 ACR/ARHP Annual Meeting
Characteristics and Treatment Outcomes of Takayasu Arteritis in a Nationwide, Retrospective Cohort Study in Japan
Haruhito A. Uchida¹, Yoshikazu Nakaoka², Hajime Yoshifuji³, Takahiko Sugihara⁴, Yoshiko Watanabe⁵, Masayoshi Harigai⁶, Yoshihiro Arimura⁷ and Mitsuaki Isobe⁸, ¹Department of Chronic Kidney Disease and Cardiovascular Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ²Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan, ³Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ⁵First Department of Physiology, Kawasaki Medical School, Kurashiki, Japan, ⁶Tokyo Women's Medical University, Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo, Japan, ⁷Kyorin University School of Medicine, First Department of Internal Medicine, Tokyo, Japan, ⁸Sakakibara Heart Institute, Tokyo, Japan
Background/Purpose: Takayasu arteritis (TAK) typically affects young women under 40 years old, whereas patients with onset age over 40 years are occasionally observed. It still…
Abstract Number: 1883 • 2018 ACR/ARHP Annual Meeting
Infections Are Associated With Increased Risk of Giant Cell Arteritis – a Population-Based Case-Control Study From Southern Sweden
Pavlos Stamatis¹, Aleksandra Turkiewicz², Martin Englund², Goran Jönsson³, Jan-Åke Nilsson⁴, Carl Turesson⁵ and Aladdin Mohammad⁶, ¹Clinical Sciences, Rheumatology Lund, Lund University, Lund, Sweden, ²Clinical Sciences Lund, Clinical Epidemiology Unit, Lund University, Lund, Sweden, ³Clinical Sciences Lund, Department of Infection Medicine, Lund University, Lund, Sweden, ⁴Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ⁵Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁶Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden
Background/Purpose: Previous studies have implicated infections as a risk factor for giant cell arteritis (GCA). The purpose of this study was to investigate the association…
Abstract Number: 1884 • 2018 ACR/ARHP Annual Meeting
Clinical Features and Outcome of Patients with Polyarteritis Nodosa – a Global Collaborative Study
Omer Karadag^1,2, Shunsuke Furuta³, Alojzija Hočevar⁴, Ummugulsum Gazel⁵, Seerapani Gopaluni⁶, Berkan Armagan¹, Matija Tomsic⁷, Fatma Alibaz-Oner⁸, Ihsan Ertenli¹, Seza Ozen¹ and David Jayne², ¹Hacettepe University Vasculitis Center (HUVAC), Ankara, Turkey, ²Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, Cambridge, United Kingdom, ³Chiba University Hospital, Chiba, Japan, ⁴Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ⁵Rheumatology, Marmara University faculty of Medicine, Istanbul, Turkey, ⁶Medicine, University of Cambridge, Cambridge, United Kingdom, ⁷Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ⁸Department of Rheumatology, Marmara University, Faculty of Medicine, Istanbul, Turkey
Background/Purpose: Polyarteritis nodosa (PAN) is a rare subgroup of the primary systemic vasculitides. Furthermore, various subgroups of PAN have been described, such as hepatitis B…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].